{"name":"KalVista Pharmaceuticals, Ltd.","slug":"kalvista-pharmaceuticals-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KVD001 Injection","genericName":"KVD001 Injection","slug":"kvd001-injection","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"KVD001 Injection","genericName":"KVD001 Injection","slug":"kvd001-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNMkJueEF0RjJ0TzRvT2REc2J0NU1LNEYxWDVoZmJoRjEzTHlpVDlCVkRYdUhNUnN4M2xsRXRQM3NETGd3a3pKUllVdk5kTy1QNUpCeXR4T1pualo4SnF1cFVHUFJsY2tlZmJQQURFYTJzUlNRTWpoNE9PUC13MmYybUV2bDE1NGg1T3ROaFF2QkJMenByUkR3dzJHWHFWSktBb19Ra0NieWw3R3BCNzJEbWU5U2xvYTJodjAwTVhfazgyejJMY1ZTNmlEeHBRR0Zoa1dXYjlSVGg0UXU0VkZOZ3JuR0VzLXBpY3JpSUZJcDBObUlYSmZjWm9PYw?oc=5","date":"2026-03-25","type":"earnings","source":"businesswire.com","summary":"KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update - businesswire.com","headline":"KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNS3FUQ0RqbHN5QzhCX3Y0MTVWYU9FQ19SM2ZSOFU4QUFFaEwycDNDeWFzWFlWU2tMNF9aeU14UVJzVDR4elpSM09ETTB6Y2VGcmJBd0Z5QlgtVFp5dndYRDBFWWZsZUo1VVB0QVNzNTFXR3NLV2FyUmd0cVFpc01oZ1BNU0NHOTduOHZpWVdjak1rUGFtaFVUdTB0dDZLb2tJSldFdUR1OW50UV9fOW5LcUVFWUl6RFZOLTlZTDh1TFFsYk9Yc2tmYkJYSlRiRWRsWGR6SDBxWnFEWmZfRVQ5VnVvWHJ6SGZkNGxtNXFiM05VMkVEMHlzZHdScHp3RlRNSld4dmQyTDQ0T3JLTUNvUHY1S1dNdkhK?oc=5","date":"2026-01-08","type":"earnings","source":"businesswire.com","summary":"KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results - businesswire.com","headline":"KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Re","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQa1NFak1veDFYLWV5OFU3UDhjY3V0Z1NyWXFPYmVZVXBXX2RZV2VrWUJvVm9uUjMxdm1maVRPWG5nSG4wcmE3SFlSY2V5enlXS21za0xqdEl6MFQ4eEJTaVc5LW1FanUxRWphLTAyb2MzaHpMR1dxVVpYVXpHQWRPRHhDRldBOTRvbDJqLXY4U2ZtdzJhbVVselFtbzE3Vi14SklzeUUtbjh5d1BYU0NTQy1FTnN5bW5YQ25CNTBxQXBjbmpqZVVUbGY5bw?oc=5","date":"2025-07-10","type":"earnings","source":"BioSpace","summary":"KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results - BioSpace","headline":"KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPbTY5bnRUbjhHbmdxbjJTV3JZMWRQV2RhRW5OZDNpVnZaakNQZ3lLZlFBcGc0bHhDM3pTc29iM21mY2p0blJ0Z2pGNlFEcWpCX0p5LWU4ZlhueDU3U1MzU2IyRFJkTmdkNDBzRE5xLWlPMUE2TV9pbDhYbjluVUJqb0F6VGtZaGdHVnlEMV9HVFVNcHMtWklnTGx6TjJuZmdpWU4tWS1oekltRFFEZlJmUlZsbGFtXzEzRUxBaG5mWkxUM1lfdVE?oc=5","date":"2025-07-07","type":"regulatory","source":"Reuters","summary":"US FDA approves KalVista's oral swelling disorder drug, shares rise - Reuters","headline":"US FDA approves KalVista's oral swelling disorder drug, shares rise","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPd3k3MU93Y3gyQVlQcXcyUjZXMnBNZ1podk5VMG8yampqTW44LUlSZlZmeEhPeXY2Qkx1ZnhKUkVEVFpzelB1VjliTFRyZU1sQzl5cE5zMlRGdjhKbG1yaHZOeVFxT0xGZHFOVW42SWFSbTdpbzFqd01iRURocGdOb2o0WjVkY01nQVNIUEVnUl8wU2IyQ3hKMmRYY2dhZ1dRX2t3dDBkVUo1Zw?oc=5","date":"2025-07-07","type":"regulatory","source":"Fierce Pharma","summary":"KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly - Fierce Pharma","headline":"KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOTm5KVmRTMFJOVnhUSGcwYzFUazkzd2FrWmFQMEFOOHU1ODFzM1dpU0xfdlIwQktaaVFScG5ab0RLcWk2azNvdE5VSnE2UlhLajAtTUxGYm9HZkFkQjNOQ0s0N1REaFlFcnpUbVYxcXc1VFhNQXZRR0VlVl8zX2J0YVcyRG56a3BuaFFIbGxrMFMyLTlkcTFleFJBWHpoQkxn?oc=5","date":"2025-07-07","type":"regulatory","source":"BioWorld News","summary":"Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld News","headline":"Missed PDUFA history as Kalvista wins FDA approval for HAE","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQbGZfMy1jaEdrYmxiVUlkbm4tN0JSZDFIWXk3SmdweTNwY0QwdG02ZnhjR0JfTWZ1SG1kSGQ4UThTZlQ4eHRvckcwc1hfSDAxVzBSa3BSXzVfaElVeEh1NXl0SHdYUmZadUNEcjB1RGhucVpCZ2EtQl9GSFBMdlN1ZnNURV9tQk9PREhkLWhidDgxaTRhUTJ2RjQ0U19Fb0o4cDUzWm1UWUNWTm9uRDJJQUhjUGdYeFVkM04waFJzcHZTQ0FqZTVZZjYxRGVvWi02c1E?oc=5","date":"2025-07-07","type":"deal","source":"PR Newswire","summary":"Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat) - PR Newswire","headline":"Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-07","type":"regulatory","source":"ET Pharma","summary":"US FDA approves KalVista Pharma's swelling disorder drug, shares rise - ET Pharma","headline":"US FDA approves KalVista Pharma's swelling disorder drug, shares rise","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOTkZ5T1A3ZVE5ZTlSZGhJc3lTNi13SWM1ekVReTFvY290SWw5T1pnd3MzMXVOTEtuWFQ1czIwWW9ob3lZTzdVYnNLUno1bmIxZl9KNk94eG9kY3ctTDhaakc0RnRwNk9IS01ZbXYzcDAwUG1STFFKWDF0V1JsN01Ca2NQN0Ixd3MtWlpQVjk3T1lqclVwVzV6T08xODduaVhBLTVFbGVXcmRlUTNLR1BmU0RCbk9sZDR4eGFsU2Q0UDF2dUFMY2RjalBxWGcxS1VpM2VQLTdrRFRTUQ?oc=5","date":"2025-06-26","type":"regulatory","source":"Newswire Canada","summary":"Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada - Newswire Canada","headline":"Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZ3hYWUlUOG5BeWNBU1RDRVZZbEFHNzBQV1drQ3R3MFNRWWpzWUVRS3p0eDFxUU12RTBCT3U0bmh3bWZ1WHZLcXppS1dEVXZuc1Axb0NVUmVyakFmOEVhTnRNMVlya1N5M05xM1c5SjI1ZFFSYXljaEFsV2lIaHhpSkYxX1h4anhMcGdPRlBFZS14c2hoQU9vcEhGWFdHSXVPSUpqaXItYy1JVFFnVWRWNThPLTNsQQ?oc=5","date":"2025-06-16","type":"regulatory","source":"Fierce Biotech","summary":"FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision - Fierce Biotech","headline":"FDA's 'heavy workload' blamed for delays to KalVista's angioedema drug approval decision","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNX3E4a3hJSDI3d3psbzV6T2xJeWhYS1g2TkVxbWVRalowNTI3WGJkbDBzQ2lMWHdvOExDYmFTaDhnY2htMENIb1JyaFY0RU9OY05NX2diSXd5SnRmTlhCTDVSTnUxcEpQSXhUdEZYMWctazJnU3lYVldkd1o1WU0zLV8wS0gycTBKdkpISHlUY2Fab1VYWDRSN2JHYncwaDQxWENNcHhzRDI?oc=5","date":"2025-06-16","type":"regulatory","source":"BioPharma Dive","summary":"FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’ - BioPharma Dive","headline":"FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1QTURxM1Z5SlVHbDRod0IzWFhZMm8zdXdkaGd1VW9yMWk4QWJFUW1fbDVaU1ZKTEFyanZjeVA4WkxGbnRWS2VxRXlOS1ZJRFMzcG93?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"KALV Stock Price, News & Analysis | Kalvista Pharm - Stock Titan","headline":"KALV Stock Price, News & Analysis | Kalvista Pharm","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}